HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Hemodynamic Frontiers in Heart Failure Registry
University of Kansas Medical Center
2,000 participants
Oct 21, 2022
OBSERVATIONAL
Conditions
Summary
The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.
Eligibility
Inclusion Criteria2
- All patients would have been or will be implanted per indications from FDA approval/CHAMPION trial. These would be patients with NYHA (New York Heart Association) Class III heart failure who had a prior hospitalization.
- Patients who meet the expanded FDA indication (BNP elevation without hospitalization or NYHA class II).
Exclusion Criteria3
- Patients less than 18 years of age.
- Pregnant women at the scheduled time of PA pressure sensor implant.
- Patients unable or unwilling to have continuity of care in the heart failure clinic.
Interventions
We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06425848